<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2954-4122</journal-id>
<journal-title><![CDATA[Archivos de neurociencias (México)]]></journal-title>
<abbrev-journal-title><![CDATA[Arch. Neurocien. (Mex.)]]></abbrev-journal-title>
<issn>2954-4122</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Neurología y Neurocirugía "Manuel Velasco Suárez"]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2954-41222022000100029</article-id>
<article-id pub-id-type="doi">10.31157/an.vi.301</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Enfermedad de Fabry y Enfermedad Vascular Cerebral]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pérez-Jovel]]></surname>
<given-names><![CDATA[Enrique]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cano-Nigenda]]></surname>
<given-names><![CDATA[Vanessa]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Manrique-Otero]]></surname>
<given-names><![CDATA[Diana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Castellanos-Pedroza]]></surname>
<given-names><![CDATA[Enrique]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Aguilar-Parra]]></surname>
<given-names><![CDATA[Lilia Georgina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Galnares-Olalde]]></surname>
<given-names><![CDATA[Javier Andrés]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Arauz]]></surname>
<given-names><![CDATA[Antonio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Salvadoreño del Seguro Social (ISSS) San Salvador ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>El Salvador</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2022</year>
</pub-date>
<volume>27</volume>
<numero>1</numero>
<fpage>29</fpage>
<lpage>38</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2954-41222022000100029&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2954-41222022000100029&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2954-41222022000100029&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen La enfermedad de Fabry (EF) es una patología genética ligada al cromosoma X (manifestada predominantemente en hombres y mujeres portadoras), causada por el déficit de la enzima &#945;-galactosidasa A (también llamada ceramida trihexosidasa) que cataliza la escisión hidrolítica de la molécula terminal de galactosa de Gb3 (globotriaosilceramida). La EF se manifiesta fenotípicamente como metabolismo inadecuado de glucoesfingolípidos, afectando membranas celulares con traducción clínica multisistémica. Además de la enfermedad vascular cerebral (EVC) que afecta principalmente a pacientes jóvenes, otras complicaciones frecuentes son las renales, cardíacas y dermatológicas. Debido a su baja prevalencia, curso crónico e inespecífico, con manifestaciones en la vida adulta joven, es difícil sospecharla. Su confirmación diagnóstica requiere medición de la actividad de la enzima &#945;-galactosidasa A, acumulación de globotriaosilceramida (Gb3), y/o determinación genética por mutación del gen GLA (gen para la galactosidasa Xq22.1). Al momento, no hay tratamiento curativo para la EF, pero sí tratamiento sintomático y para las secuelas que genera a nivel sistémico. El objetivo de esta revisión es brindar al clínico una perspectiva general de los aspectos epidemiológicos, fisiopatológicos y clínicos de la EF, con especial interés en su expresión como EVC, con la finalidad de sospecharla como diagnóstico diferencial en el momento de afrontarla.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[enfermedad de Fabry]]></kwd>
<kwd lng="es"><![CDATA[enfermedad vascular cerebral]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fabry]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ein Beitrag zur Kenntniss der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae)]]></article-title>
<source><![CDATA[Arch Für Dermatol Syph]]></source>
<year>1898</year>
<volume>43</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>187-200</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Case of &#8220;Angeio-Keratoma&#8221;*]]></article-title>
<source><![CDATA[Br J Dermatol]]></source>
<year>1898</year>
<volume>10</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>113-7</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pompen]]></surname>
<given-names><![CDATA[AWM]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiter]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wyers]]></surname>
<given-names><![CDATA[HJG.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Angiokeratoma corporis diffusum (universale) Fabry, as a sign of an unknown internal disease; two autopsy reports]]></article-title>
<source><![CDATA[Acta Med Scand]]></source>
<year>1947</year>
<volume>128</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>234-55</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hornbostel]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Scriba]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Excision of skin in diagnosis of Fabry&#8217;s angiokeratoma with cardio-vasorenal syndrome as phosphatide storage disease]]></article-title>
<source><![CDATA[Klin Wochenschr]]></source>
<year>1953</year>
<volume>31</volume>
<numero>3-4</numero>
<issue>3-4</issue>
<page-range>68-9</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sweeley]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
<name>
<surname><![CDATA[Klionsky]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fabry&#8217;s Disease: Classification as a Sphingolipidosis and Partial Characterization of a Novel Glycolipid]]></article-title>
<source><![CDATA[J Biol Chem]]></source>
<year>1963</year>
<volume>238</volume>
<page-range>3148-50</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brady]]></surname>
<given-names><![CDATA[RO]]></given-names>
</name>
<name>
<surname><![CDATA[Gal]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Bradley]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Martensson]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Warshaw]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Laster]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enzymatic defect in Fabry&#8217;s disease. Ceramidetrihexosidase deficiency]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1967</year>
<volume>276</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>1163-7</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schiffmann]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fabry disease. En: Handbook of Clinical Neurology]]></article-title>
<source><![CDATA[Elsevier]]></source>
<year>2015</year>
<page-range>231-48</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="">
<source><![CDATA[OMIM Fabry Disease]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Viana-Baptista]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stroke and Fabry disease]]></article-title>
<source><![CDATA[J Neurol]]></source>
<year>2012</year>
<volume>259</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1019-28</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>9</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caplan]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Biller]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Uncommon Causes of Stroke]]></source>
<year>2018</year>
<edition>3</edition>
<publisher-loc><![CDATA[Cambridge ]]></publisher-loc>
<publisher-name><![CDATA[Cambridge University Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Desnick]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Wasserstein]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Banikazemi]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fabry disease (alphagalactosidase A deficiency): renal involvement and enzyme replacement therapy]]></article-title>
<source><![CDATA[Contrib Nephrol]]></source>
<year>2001</year>
<numero>136</numero>
<issue>136</issue>
<page-range>174-92</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Spada]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pagliardini]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Yasuda]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Tukel]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Thiagarajan]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Sakuraba]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[High incidence of later-onset fabry disease revealed by newborn screening]]></article-title>
<source><![CDATA[Am J Hum Genet]]></source>
<year>2006</year>
<volume>79</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>31-40</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Clarke]]></surname>
<given-names><![CDATA[JTR.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Narrative review: Fabry disease]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2007</year>
<volume>146</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>425-33</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rolfs]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Böttcher]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Zschiesche]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Morris]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Winchester]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Bauer]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study]]></article-title>
<source><![CDATA[Lancet Lond Engl]]></source>
<year>2005</year>
<volume>366</volume>
<numero>9499</numero>
<issue>9499</issue>
<page-range>1794-6</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barinagarrementeria]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Figueroa]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Huebe]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cantú]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cerebral Infarction in PeopleUnder 40 Years I]]></article-title>
<source><![CDATA[Cerebrovasc Dis]]></source>
<year>1996</year>
<volume>6</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>75-9</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reisin]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Mazziotti]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cejas]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
<name>
<surname><![CDATA[Zinnerman]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bonardo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Pardal]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of Fabry Disease in Young Patients with Stroke in Argentina]]></article-title>
<source><![CDATA[J Stroke Cerebrovasc Dis]]></source>
<year>2018</year>
<volume>27</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>575-82</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lanthier]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Saposnik]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Lebovic]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Pope]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Selchen]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Moore]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of Fabry Disease and Outcomes in Young Canadian Patients With Cryptogenic Ischemic Cerebrovascular Events]]></article-title>
<source><![CDATA[Stroke]]></source>
<year>2017</year>
<volume>48</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1766-72</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Germain]]></surname>
<given-names><![CDATA[DP.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fabry disease. Orphanet]]></article-title>
<source><![CDATA[J Rare Dis]]></source>
<year>2010</year>
<volume>5</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>30</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caplan]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
<name>
<surname><![CDATA[Bogousslavsky]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Uncommon Causes of Stroke]]></source>
<year>2008</year>
<edition>2</edition>
<publisher-loc><![CDATA[Cambridge ]]></publisher-loc>
<publisher-name><![CDATA[Cambridge University Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Desnick]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ioannou]]></surname>
<given-names><![CDATA[YA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#945;-Galactosidase A deficiency: Fabry disease]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Scriver CR]]></surname>
<given-names><![CDATA[Beaud]]></given-names>
</name>
<name>
<surname><![CDATA[Sly]]></surname>
<given-names><![CDATA[WS]]></given-names>
</name>
<name>
<surname><![CDATA[Valle]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[The metabolic bases of Inherited Disease]]></source>
<year>2001</year>
<edition>8</edition>
<page-range>3733-74</page-range><publisher-loc><![CDATA[New York ]]></publisher-loc>
<publisher-name><![CDATA[MacGraw-Hill]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Branton]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Schiffmann]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kopp]]></surname>
<given-names><![CDATA[JB.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Natural history and treatment of renal involvement in Fabry disease]]></article-title>
<source><![CDATA[J Am Soc Nephrol JASN]]></source>
<year>2002</year>
<volume>13</volume>
<numero>S2</numero>
<issue>S2</issue>
<page-range>S139-43</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="">
<collab>Genzyme, a Sanofi Company</collab>
<source><![CDATA[Fabry Disease Registry Protocol. clinicaltrials.gov]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kolodny]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Fellgiebel]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hilz]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Sims]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Caruso]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Phan]]></surname>
<given-names><![CDATA[TG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cerebrovascular involvement in Fabry disease: current status of knowledge]]></article-title>
<source><![CDATA[Stroke]]></source>
<year>2015</year>
<volume>46</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>302-13</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sims]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Politei]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Banikazemi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry]]></article-title>
<source><![CDATA[Stroke]]></source>
<year>2009</year>
<volume>40</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>788-94</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mitsias]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Levine]]></surname>
<given-names><![CDATA[SR.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cerebrovascular complications of Fabry&#8217;s disease]]></article-title>
<source><![CDATA[Ann Neurol]]></source>
<year>1996</year>
<volume>40</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>8-17</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mendez]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Stanley]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Medel]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Tedesco]]></surname>
<given-names><![CDATA[DT.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The vascular dementia of Fabry&#8217;s disease]]></article-title>
<source><![CDATA[Dement Geriatr Cogn Disord]]></source>
<year>1997</year>
<volume>8</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>252-7</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schermuly]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Müller]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Müller]]></surname>
<given-names><![CDATA[K-M]]></given-names>
</name>
<name>
<surname><![CDATA[Albrecht]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Keller]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Yakushev]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neuropsychiatric symptoms and brain structural alterations in Fabry disease]]></article-title>
<source><![CDATA[Eur J Neurol]]></source>
<year>2011</year>
<volume>18</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>347-53</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Utsumi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Yamamoto]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kase]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Takata]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Okumiya]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Saito]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[High incidence of thrombosis in Fabry&#8217;s disease]]></article-title>
<source><![CDATA[Intern Med Tokyo Jpn]]></source>
<year>1997</year>
<volume>36</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>327-9</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oto]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kart]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kadayifçilar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ozdemir]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Aydin]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Retinal vein occlusion in a woman with heterozygous Fabry&#8217;s disease]]></article-title>
<source><![CDATA[Eur J Ophthalmol]]></source>
<year>1998</year>
<volume>8</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>265-7</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="">
<source><![CDATA[Primer on Cerebrovascular Diseases]]></source>
<year>2021</year>
<edition>2nd</edition>
</nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chamoles]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Blanco]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gaggioli]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fabry disease: enzymatic diagnosis in dried blood spots on filter paper]]></article-title>
<source><![CDATA[Clin Chim Acta]]></source>
<year>2001</year>
<volume>308</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>195-6</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Villalobos]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Politei]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Martins]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Cabrera]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Amartino]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Lemay]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fabry Disease in Latin America: Data from the Fabry Registry]]></article-title>
<source><![CDATA[JIMD Rep]]></source>
<year>2012</year>
<volume>8</volume>
<page-range>91-9</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meikle]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ranieri]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Simonsen]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Rozaklis]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ramsay]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Whitfield]]></surname>
<given-names><![CDATA[PD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Newborn screening for lysosomal storage disorders: clinical evaluation of a two-tier strategy]]></article-title>
<source><![CDATA[Pediatrics]]></source>
<year>2004</year>
<volume>114</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>909-16</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mechtler]]></surname>
<given-names><![CDATA[TP]]></given-names>
</name>
<name>
<surname><![CDATA[Stary]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Metz]]></surname>
<given-names><![CDATA[TF]]></given-names>
</name>
<name>
<surname><![CDATA[De Jesús]]></surname>
<given-names><![CDATA[VR]]></given-names>
</name>
<name>
<surname><![CDATA[Greber-Platzer]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pollak]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria]]></article-title>
<source><![CDATA[Lancet Lond Engl]]></source>
<year>2012</year>
<volume>379</volume>
<numero>9813</numero>
<issue>9813</issue>
<page-range>335-41</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rombach]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Smid]]></surname>
<given-names><![CDATA[BE]]></given-names>
</name>
<name>
<surname><![CDATA[Linthorst]]></surname>
<given-names><![CDATA[GE]]></given-names>
</name>
<name>
<surname><![CDATA[Dijkgraaf]]></surname>
<given-names><![CDATA[MGW]]></given-names>
</name>
<name>
<surname><![CDATA[Hollak]]></surname>
<given-names><![CDATA[CEM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: Effectiveness of ERT in different disease stages]]></article-title>
<source><![CDATA[J Inherit Metab Dis. Wiley Online Library]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lenders]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Nordbeck]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Kurschat]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Karabul]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kaufeld]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hennermann]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of Fabry&#8217;s Disease With Migalastat: Outcome From a Prospective Observational Multicenter Study (FAMOUS)]]></article-title>
<source><![CDATA[Clin Pharmacol Ther]]></source>
<year>2020</year>
<volume>108</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>326-37</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Michaud]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mauhin]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Belmatoug]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Garnotel]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bedreddine]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Catros]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[When and How to Diagnose Fabry Disease in Clinical Pratice]]></article-title>
<source><![CDATA[Am J Med Sci]]></source>
<year>2020</year>
<volume>360</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>641-9</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saarinen]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Sillanpää]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kantola]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A male Fabry disease patient treated with intravenous thrombolysis for acute ischemic stroke]]></article-title>
<source><![CDATA[J Clin Neurosci Off J Neurosurg Soc Australas]]></source>
<year>2015</year>
<volume>22</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>423-5</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mehta]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Beck]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Eyskens]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Feliciani]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kantola]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Ramaswami]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fabry disease: a review of current management strategies]]></article-title>
<source><![CDATA[QJM]]></source>
<year>2010</year>
<volume>103</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>641-59</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Michaud]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mauhin]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Belmatoug]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Garnotel]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bedreddine]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Catros]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[When and How to Diagnose Fabry Disease in Clinical Pratice]]></article-title>
<source><![CDATA[Am J Med Sci]]></source>
<year>2020</year>
<volume>360</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>641-9</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
